"RenalytixAI Scores $29M for AI-Based Kidney Disease Diagnostics" - Amirah Al Idrus
RenalytixAI, which makes artificial intelligence-based clinical diagnostics for kidney disease, has raised $29 million to develop and commercialize two tests. The first spots kidney disease early, while the second is designed for managing rejection in kidney transplant patients. "Kidney disease is a major challenge for healthcare systems around the globe," said Barbara Murphy, MD, chair of the Samuel Bronfman department of medicine and dean for clinical integration and population health at the Icahn School of Medicine at Mount Sinai, who sits on RenalytixAI’s board of directors and chairs its scientific advisory board. "We're responding to this critical unmet need by developing two products that will identify patients at risk for kidney disease progression and dialysis, and categorize the type of risk that will be experienced by kidney transplant patients,” she said.
— Barbara Murphy, MD, Chair, Samuel Bronfman Department of Medicine, Dean, Clinical Integration and Population Health, Icahn School of Medicine at Mount Sinai
— Erik Lium, MD, Executive Vice President, Mount Sinai Innovation Partners
Additional coverage: